Browse > Article

Clinical Usefulness of Dopamine Transporter Imaging  

Kim, Jong-Min (Departments of Neurology, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital)
Kim, Yu-Kyeong (Departments of Nuclear Medicine, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital)
Kim, Sang-Eun (Departments of Nuclear Medicine, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital)
Jeon, Beom-S. (Departments of Neurology, Seoul National University College of Medicine, MRC and BK-21, Clinical Research Institute, Seoul National University Hospital and Bundang Hospital)
Publication Information
Nuclear Medicine and Molecular Imaging / v.41, no.2, 2007 , pp. 152-157 More about this Journal
Abstract
Imaging of the dopamine transporter (DAT) provides a marker for the integrity of presynaptic nigrostriatal dopaminergic system. DAT density is reduced in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. In patients with suspicious parkinsonism, normal DAT imaging suggests an alternative diagnosis such as essential tremor, vascular parkinsonism, or drug-induced parkinsonism. DAT imaging is a useful tool to aid clinician's differential diagnosis in parkinsonism.
Keywords
dopamine transporter; parkinsonism; Parkinson disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-68   DOI   ScienceOn
2 Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002;58:1489-93   DOI   ScienceOn
3 Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-3
4 Marti Masso JF, Carrera N, Urtasun M. Drug-induced parkinsonism: a growing list. Mov Disord 1993;8:125   DOI
5 Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28: 99-102   DOI   ScienceOn
6 Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;Suppl 7:S28-33
7 Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, et al. Dopamine transporter imaging with [$^{123}I$]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-4   DOI
8 Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303-12   DOI   ScienceOn
9 Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol 2005;62:351-2   DOI   ScienceOn
10 Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [$^{123}I$] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50:9-24
11 Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [$^{123}I$]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-67   DOI   ScienceOn
12 Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54: 93-101   DOI   ScienceOn
13 Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, et al. [$^{123}I$]-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-23   DOI   ScienceOn
14 Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 2002;17:568-75   DOI   ScienceOn
15 Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]beta-CIT singlephoton emission computed tomography is normal in doparesponsive dystonia. Ann Neurol 1998;43:792-800   DOI   ScienceOn
16 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson󰡑s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4   DOI
17 Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [$^{123}I$]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-32   DOI   ScienceOn
18 Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol 1985;17:329-33   DOI   ScienceOn
19 Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724-7   DOI   ScienceOn
20 Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible druginduced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 1982;39:644-6   DOI   ScienceOn
21 Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61   DOI   ScienceOn
22 Winikates J Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102   DOI   ScienceOn